Profile data is unavailable for this security.
About the company
Renovaro Inc. specializes in cancer diagnostics and therapeutics powered by artificial intelligence (AI). The Company operates through two subsidiaries: Renovaro Biosciences, Inc. (Renovaro Biosciences) and Renovaro Cube. Renovaro Biosciences is a biotechnology company intending to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) infections. Renovaro Cube is an AI-driven healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed an AI platform that analyzes genetics using Explainable AI to provide earlier and more accurate cancer diagnosis. This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.
- Revenue in USD (TTM)0.00
- Net income in USD-80.65m
- Incorporated2011
- Employees25.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
More ▼
Mergers & acquisitions
| Acquired company | RENB:NAQ since announced | Transaction value |
|---|---|---|
| Gedi Cube Bv | -81.25% | -- |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | 18.86m | -123.53m | 94.07m | 69.00 | -- | 0.8136 | -- | 4.99 | -26.06 | -25.94 | 3.74 | 16.41 | 0.167 | -- | 8.28 | 273,304.30 | -109.42 | -65.23 | -169.41 | -154.37 | 87.21 | -- | -655.07 | -100.61 | -- | -- | 0.0055 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 95.60m | 18.00 | -- | 0.6292 | -- | 145.06 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 96.14m | 45.00 | -- | 1.08 | -- | 28.39 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 96.26m | -- | 5.58 | 0.1948 | 49.78 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 96.52m | 40.00 | -- | 1.09 | -- | 170.07 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| MDxHealth SA | 80.74m | -40.80m | 98.00m | 300.00 | -- | -- | -- | 1.21 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 98.07m | 20.00 | -- | 2.06 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Hillevax Inc | 0.00 | -150.28m | 98.12m | 90.00 | -- | 0.5289 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| Renovaro Inc | 0.00 | -80.65m | 99.78m | 25.00 | -- | 0.7248 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.8513 | 0.00 | -- | -- | 0.00 | -72.84 | -39.86 | -89.56 | -42.11 | -- | -- | -- | -- | -- | -10.76 | 0.0182 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| CervoMed Inc | 9.65m | -5.04m | 100.20m | 8.00 | -- | 2.00 | -- | 10.38 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 103.34m | 47.00 | -- | 3.23 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Genelux Corp | 8.00k | -26.54m | 103.61m | 23.00 | -- | 2.71 | -- | 12,950.80 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -117.88m | 103.83m | 143.00 | -- | 0.4908 | -- | -- | -1.70 | -1.70 | 0.00 | 2.57 | 0.00 | -- | -- | 0.00 | -49.20 | -37.03 | -53.58 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Assembly Biosciences Inc | 28.33m | -40.80m | 104.31m | 65.00 | -- | 4.01 | -- | 3.68 | -7.54 | -7.54 | 5.14 | 4.09 | 0.373 | -- | -- | 435,784.60 | -53.73 | -39.69 | -79.14 | -44.03 | -- | -- | -144.05 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 104.80m | 127.00 | -- | 1.96 | -- | 20.96 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 105.13m | 9.00 | -- | 17.69 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Renovaro Inc's reporting currency: US Dollar USD
8.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.57m | 3.78% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.39m | 2.30% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.73m | 1.17% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.28m | 0.87% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 399.97k | 0.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 294.60k | 0.20% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 198.97k | 0.14% |
| BlackRock Investment Management LLCas of 30 Jun 2024 | 131.84k | 0.09% |
| The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 107.15k | 0.07% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 103.17k | 0.07% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
